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Objective: To directly compare aripiprazole once-monthly 400 mg (AOM 400) and paliperidone palmitate once-
monthly (PP) on the Heinrichs–Carpenter Quality-of-Life Scale (QLS), a validated health-related quality of life
and functioning measure in schizophrenia.
Method: This 28-week, randomized, non-inferiority, open-label, rater-blinded, head-to-head study (QUALIFY)
of AOM 400 and PP in adult patients (18–60 years) comprised oral conversion, initiation of AOM 400 or PP
treatment, and continuation with intramuscular injections every 4 weeks. The primary endpoint assessed non-
inferiority and superiority on QLS total score analyzed using a mixed model for repeated measurements.
Results: Of 295 randomized patients, 100/148 (67.6%) of AOM 400 and 83/147 (56.5%) of PP patients completed
28 weeks of treatment. A statistically signiﬁcant least squares mean difference in change from baseline to week
28 on QLS total score (4.67 [95%CI: 0.32;9.02], p = 0.036) conﬁrmed non-inferiority and established superiority
of AOM 400 vs PP. There were also signiﬁcant improvements in Clinical Global Impression — Severity scale and
the Investigator's Assessment Questionnaire for AOM 400 vs PP, and pre-deﬁned sub-group analyses revealed
a consistent pattern of signiﬁcance favoring AOM 400 in patients ≤35 years. Common treatment-emergent
adverse events in the treatment continuation phaseweremore frequentwith PP vs AOM400, and adverse events
were the most frequent reason for discontinuation (27/137 [19.7%] for PP and 16/144 [11.1%] for AOM 400). All-
cause discontinuation was numerically lower with AOM 400.
Conclusion: Superior improvements on clinician-rated health-related quality of life and a favorable tolerability
proﬁle suggest greater overall effectiveness for aripiprazole once-monthly vs paliperidone palmitate.
ClinicalTrials.gov identiﬁer: NCT01795547.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Schizophrenia is a chronic disorder characterized by frequent
relapses that have severe consequences for patients' quality of life, in-
cluding occupational and psychosocial function, as well as economic
burden for the patients and their families. Since patientsmay not return
to previous levels of functioning following relapse (Emsley et al., 2013;
Lieberman et al., 2006), early treatment intervention is important and
has the potential to change the course of the illness (Stahl, 2014).. This is an open access article underAnother prerequisite for successful treatment is patient adherence,
which is often poor in schizophrenia (Perkins, 2002).
Long-acting injectable antipsychotics (LAIs) may increase long-term
adherence to treatment andmay reduce the risk of relapse and improve
patient functioning (Kishimoto et al., 2013). Both aripiprazole once-
monthly 400 mg (AOM 400) and paliperidone palmitate once-monthly
(PP) are atypical LAIs with demonstrated efﬁcacy in schizophrenia
(Fleischhacker et al., 2014; Hough et al., 2010; Kane et al., 2012;
Nasrallah et al., 2010). However, they have different pharmacological
mechanisms: aripiprazole is a partial agonist at dopamineD2 and seroto-
nin 5-HT1A receptors and an antagonist at 5HT2A receptors while
paliperidone is an antagonist at D2 and 5HT2A receptors. In addition tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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treatment (Hasan et al., 2013), and studies of treatment effectiveness
(comprising both efﬁcacy and tolerability) on more clinically relevant
endpoints beyond traditional psychopathology are necessary to evaluate
the effect of treatments on patient functioning and quality of life, both of
which are inversely predictive of relapse (Boyer et al., 2013).
The Heinrichs–Carpenter Quality-of-Life Scale (QLS) was selected as
the primary endpoint reﬂecting a key long-term treatment goal for both
clinician and patient. It is a clinician-rated scale derived from a semi-
structured patient interview that is widely used in psychopharmacolog-
ical evaluation of treatments for schizophrenia (Lewis et al., 2006). The
QLS is a health-related quality-of-life scale focused on intrapsychic,
social, and negative symptoms and their consequences for functioning
in schizophrenia (Heinrichs et al., 1984). The QLS total score measures
effects beyond functioning in patients with schizophrenia; it also as-
sesses the richness of personal experience, the quality of interpersonal
relations, and productivity in occupational roles.
TheQUALIFY (QUAlity of LIfewith AbiliFYMaintena®) study is oneof
very few randomized studies that directly compare two atypical LAIs
and is the ﬁrst to compare two atypical LAIs with different mechanisms
of action on health-related quality of life and functioning. Previous
head-to-head studies have compared effects of LAIs on classical mea-
sures of psychopathology and have consistently showed non-inferiority
between different LAIs (Fleischhacker et al., 2012; Li et al., 2011;
Pandina et al., 2011). Superiority of one atypical LAI vs another has not
been previously demonstrated.
The primary objective of this studywas to compare the effectiveness
of 28-week treatmentwith AOM400 to PP in adult patientswith schizo-
phrenia on the QLS using a non-inferiority hypothesis; if met, a pre-
deﬁned test of superiority would be conducted. Additional objectives
were to compare safety and tolerability of the treatments.
2. Materials and methods
2.1. Study design
This phase 3b, multicenter, 28-week, open-label, rater-blinded, ran-
domized, non-inferiority study (NCT01795547) compared the effective-
ness of two atypical LAIs, AOM 400 (reduction of the maintenance dose
to 300 mg based on individual patient tolerability was permitted) and
PP (ﬂexible dosing, per label, with 50 to 150mg/month as paliperidoneScreening
(<2 weeks)
Oral conversion
(3 weeks)
LAI initiation
(5 weeks)
Patients were 
randomized 1:1
1 week oral aripiprazole (10–3
Injection 1 (day 28): AOM 40
oral aripiprazole (10–20 mg/da
Injection 1 (day 21):150 mg [E
Canada] or 234 mg [US]
Injection 2 (day 28): 100 mg [
Canada] or 156 mg [US]
Baseline Assessments at weeks 2 & 3 Assessments at weeks
Oral paliperidone
3–12 mg/day
Oral aripiprazole
5–30 mg/day
PP
AOM 400
R
Fig. 1. Study design. After screening for 7–14 days, eligible patients were randomly assigned (1
conversion period to either oral aripiprazole (5–30 mg/day) or oral paliperidone (3–12 mg/da
gradually increasing doses of oral aripiprazole or paliperidone. (ii) Patients who tolerated oral
Patients randomized to AOM 400 continued with oneweek of oral aripiprazole treatment, then
current oral aripiprazole treatment (recommended supplemental dosewas 10–20mg/day depe
and Canada], 234 mg [US]) at the end of week 3 and discontinued oral paliperidone. One week
treatment continued asﬁvemonthly injections of AOM400or PP, starting atweek 8. Injections c
who received at least one dose of study medication were followed for safety for 4 weeks after[EU and Canada], equivalent to 78 to 234 mg/month as paliperidone
palmitate [US]). The study design is illustrated in Fig. 1.
Patients were enrolled from 71 study sites in 10 countries (Canada,
Czech Republic, Germany, Estonia, Spain, France, United Kingdom,
Italy, Sweden, United States). The study took place from February
2013 through September 2014 and was in compliance with the princi-
ples of Good Clinical Practice and in accordance with the Declaration
of Helsinki.
2.2. Patients
Eligible patients includedmen andwomen aged 18 to 60 years, with
DSM-IV-TR–deﬁned schizophrenia. The study included stable, i.e., not
acutely psychotic, patients needing a change from current oral antipsy-
chotic treatment due to inadequate response, poor tolerability, or lack of
adherence and who, in the judgment of the investigator, would beneﬁt
from LAI treatment. A Clinical Global Impression — Severity scale
(CGI-S) score ≥3 (mildly ill) and ≤5 (markedly ill) was required at
both the screening and baseline visits, and treatment with oral antipsy-
chotics was required for 3 months prior to screening. To allow pre-
speciﬁed comparisons of changes in outcome measures for younger
and older cohorts, randomizationwas stratiﬁed by age, and recruitment
targeted one third of patients ≤35 years.
Patients with a diagnosis of psychiatric disorder or Axis I disorder
(DSM-IV-TR criteria) other than schizophrenia, substance use disorder
(except nicotine) that according to the investigator's judgment could
compromise the patient's compliance with the study procedures, intol-
erance to or previous lack of efﬁcacy with oral aripiprazole, risperidone,
or paliperidone, or previous treatment with LAIs within 6 months prior
to screening were excluded from participation in the study. Based on
disease severity criteria, patients exhibiting acute exacerbation of psy-
chotic symptoms, hospitalization for N3 months at the time of the
screening visit, at signiﬁcant risk of harming self or others, refractori-
ness to antipsychotic treatment, or with a history of failure to respond
to/responding only to clozapine treatment were also excluded.
2.3. Assessments
The primary endpoint was change from baseline to week 28 on the
QLS total score. The QLS consists of 21 items in 4 domains: Interper-
sonal Relations (8 items), Instrumental Role (4 items), IntrapsychicLAI continuation,
once-monthly (20 weeks)
Safety 
follow-up
(4 weeks)
0 mg/day) 
0, with 2 weeks
y)
U and  
EU and 
(50–150 mg/month [EU and Canada]
or 78–234 mg [US])
 4 & 8 Five monthly assessments starting week 12
PP
5 injections
AOM 400 
:1) to AOM 400 or PP treatment groups. The study comprised three phases: (i) a 3-week
y) during which patients were tapered from previous antipsychotic medication(s) while
medication initiated the assigned LAI treatment with AOM 400 or PP in a 5-week phase.
received the ﬁrst intramuscular (IM) injection at week 4, accompanied by 2weeks of con-
nding on previous dose). Patients randomized to PP received one IM injection (150mg [EU
later, a second PP IM injection was given (100 mg [EU and Canada], 156mg [US]). (iii) LAI
ould be given up to twodays before orﬁvedays after the scheduledmonthly dose. Patients
the last study visit.
Table 1
Patient baseline demographics and disease severity.
Aripiprazole
once-monthly
400 mg (AOM 400)
Paliperidone
palmitate
once-monthly (PP)
Patients randomized, n 148 147
Patients treated, n (%) 144 (97.3) 137 (93.2)
Age, mean (SD), years 42.6 (10.9) 41.2 (10.7)
Age, n (%):
≤35 years 42 (29.2) 38 (27.7)
N35 years 102 (70.8) 99 (72.3)
Age at schizophrenia onset,
mean (SD), years
28.5 (10.7) 26.8 (9.5)
Gender male, n (%) 86 (59.7) 82 (59.9)
Race, n (%):
White 101 (70.1) 95 (69.3)
Black or African American 41 (28.5) 35 (25.5)
Asian 1 (0.7) 3 (2.2)
Other 0 (0.0) 3 (2.2)
Unknown 1 (0.7) 1 (0.7)
BMI, mean (SD) 29.9 (6.3)a 29.1 (6.3)
b18.5 kg/m2, n (%) 0 (0.0) 1 (0.7)
18.5 to b25 kg/m2, n (%) 30 (20.8) 35 (25.5)
25 to b30 kg/m2, n (%) 50 (34.7) 50 (36.5)
≥30 kg/m2, n (%) 63 (43.8) 51 (37.2)
Baseline severity scores:
Full analysis set (FAS), n (%) 136 132
QLS total score, mean (SD) 66.0 (21.7) 62.9 (21.5)
CGI-S score, mean (SD) 4.0 (0.65) 4.0 (0.65)
There were no signiﬁcant differences in demographics or baseline disease severity
between patients in the AOM 400 and PP groups. BMI: body mass index, CGI-S: Clinical
Global Impression— Severity of Illness, SD: Standard deviation, QLS: Heinrichs–Carpenter
Quality-of-Life Scale.
a n = 143.
Screening 
n=381
Randomization 
n=295 (77.4%)
Screening failures
n=86 (22.6%)
Adverse events: n=16 (11.1%)
Lack of efficacy: n=8 (5.6%)
Withdrawal of consent: n=7 (4.9%) 
Protocol violation: n=6 (4.2%)
Lost to follow-up: n=2 (1.4%) 
Non-compliance: n=1 (0.7%)
Other: n=4 (2.8%)
Adverse events: n=27 (19.7%)
Lack of efficacy: n=3 (2.2%)
Withdrawal of consent: n=12 (8.8%)
Protocol violation: n=4 (2.9%)
Lost to follow-up: n=5 (3.6%) 
Non-compliance: n=1 (0.7%)
Other: n=1 (0.7%)
AOM 400
n=148
Completed 
n=83 (56.5%)
Discontinued
n=44 (29.7%)
Completed
n=100 (67.6%)
Patient met exclusion criteria (n=55)
Withdrawal of consent (n=14)
Did not meet inclusion criteria (n=12)
Lost to follow-up (n=5)
Other (n=8)
Not treated 
n=10 (6.8%)
Discontinued
n=54 (36.7%)
PP
n=147
Not treated
n=4 (2.7%)
Fig. 2. Patient disposition and primary reason for discontinuation and screening failure. Discontinuation percentages are calculated based on the number of treated patients. Each patient
could havemore than one reason for screening failure. One patient in the PP group did not complete the study completion panel in a late visit, therefore no reason for discontinuationwas
recorded.
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items). Each itemwas scored on a 7-point Likert scale, from 0 (severe
impairment) to 6 (normal or unimpaired functioning). The score is
calculated for each domain and the total score ranges from 0 to 126.
The CGI-S provides the clinician's impression of the patient's current
state of mental illness on a 7-point scale ranging from 1 (normal–not at
all ill) to 7 (among the most extremely ill patients) (Guy, 1976). The
Investigator's Assessment Questionnaire (IAQ) is a validated, clinician-
rated scale designed to assess relative effectiveness (efﬁcacy, safety
and tolerability) of antipsychotic medications in patients with schizo-
phrenia (Tandon et al., 2005). The IAQ consists of 12 equally weighted
items: positive symptoms, negative symptoms, other efﬁcacy symp-
toms, somnolence, weight gain, signs and symptoms of prolactin eleva-
tion, akathisia, other extrapyramidal symptoms, other safety or
tolerability issues, cognition, energy, and mood. For each item, the cur-
rentmedication is comparedwith previous antipsychoticmedication on
a ﬁve-point scale from 1 (much better) to 5 (much worse). Total IAQ
scores range from 12 to 60with lower IAQ total scores indicating better
relative treatment effectiveness.
The QLS and IAQ scales were administered by a rater blinded to the
treatment (without access tomedical records, study ﬁles, or studymed-
ications) trained for consistency and reliability. Raters for the remaining
assessments and questionnaires were not blinded to the patient's treat-
ment. IAQ and CGI-S were pre-deﬁned secondary endpoints. Additional
endpoints will be reported elsewhere.
2.4. Statistical analyses
A difference of 5 points on QLS total score was deﬁned as clinically
meaningful in a comparative effectiveness study (CUtLASS) between
ﬁrst- and second-generation antipsychotics (Jones et al., 2006). This
was supported by results from the STAR study (Taylor et al., 2008) in
which a difference of 6 points between aripiprazole and standard
of care was observed. Therefore, the study was powered based on a
5-point non-inferiority margin (Wiens, 2002). Assuming an SD of
15 in the change from baseline to week 28, a treatment difference
of 1, a power of 80%, and a 30% discontinuation rate, the total sample
size was set to 286.
All effectiveness analyses were conducted using the full analysis set
(FAS), which was deﬁned as treated patients who had a valid QLS base-
line and ≥1 post-baseline QLS assessment. The safety sample included
all patients who received at least one dose of study medication (oral
or LAI). All effectiveness endpoints were analyzed using a mixed
model for repeated measures (MMRM) with an unstructuredcovariance matrix including baseline score-by-visit interaction, geo-
graphic region (Europe/North America), age subgroup (≤35/N35 years),
visit, and treatment-by-visit interaction as ﬁxed effects. Estimated treat-
ment differences (AOM 400 vs PP) and associated tests were made at
all study visits.
For the pre-deﬁned primary endpoint, non-inferiority criterion was
met if the lower bound of the two-sided 95% CI was greater than−5
(non-inferiority margin) for the mean treatment difference in change
from baseline in QLS at week 28 (AOM 400 vs PP). The pre-deﬁned sta-
tistical analysis plan allowed for subsequent testing for superiority of
AOM 400 over PP which was considered conﬁrmed if the lower bound
of the two-sided 95% CI was N0. As pre-deﬁned sensitivity analysis on
the primary endpoint, change from baseline to week 28 of QLS total
Fig. 3. Effects of AOM 400 and PP treatment on QLS total scores (A) and CGI-S scores (B).
Least squares mean (LSM) changes from baseline were analyzed using a mixedmodel for
repeatedmeasures (MMRM). *p b 0.05, **p b 0.01 indicate signiﬁcant differences between
treatments (AOM 400 vs PP). Error bars indicate the standard error of the LSM.
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model as in the primary analysis. The PPS comprised all patients in the
FAS who did not use disallowed concomitant medication during the
treatment period, had at least one IM injection of AOM 400 or PP, and
were rated on QLS and IAQ by a blinded rater (n=122 for AOM 400,
n=112 for PP). Additional pre-deﬁned sensitivity analyses included
analysis of co-variance (ANCOVA) using last-observation-carried-
forward (LOCF) and observed cases (OC) in the FAS.
In pre-deﬁned analyses to investigate the effect of age on treatment
outcome, all effectiveness endpoints were analyzed separately in pa-
tients ≤35 years and in those N35 years. Due to the reduced statistical
power, these sub-group analyses were considered exploratory. For the
continuous secondary endpoints (CGI-S and IAQ total score, and QLS
domain scores), a similar methodology as described for the primary
superiority analysis was applied. For all secondary analyses, differences
between treatments were tested for signiﬁcance; however, p-values
were considered nominal and were not corrected for multiple
comparisons.
The proportions of patients with an adverse event (AE) are shown
using descriptive statistics. A treatment-emergent AE (TEAE) was de-
ﬁned as an AE that started at or after the date of ﬁrst dose of oral treat-
ment and prior to the last protocol-speciﬁed contact with each patient.
TEAEswere allocated to treatment phases according to the time of onset
as follows. Oral conversion: a TEAEwith onset on or after the date ofﬁrstTable 2
Effects of AOM 400 and PP treatment on IAQ total scores at week 28 in the total and in age-str
LSM IAQ total score at week 28 (SE)
FAS AOM 400 (n=133) PP (n=13
32.32 (0.52) 33.81 (0.55)
Patients ≤35 years, FAS AOM 400 (n=40) PP (n=37
31.59 (0.86) 34.24 (1.02)
Patients N35 years, FAS AOM 400 (n=93) PP (n=94
32.52 (0.62) 33.55 (0.63)
FAS: full analysis set, LSM: least squares mean, SE: standard error.
a Pre-deﬁned secondary analysis usedMMRM to assess treatment effect on IAQ total scores a
with non-missing data in the FAS are analyzed.oral dose and prior to the LAI treatment initiation period (after week 3).
LAI treatment initiation: a TEAE with onset at or after week 3 and prior
to week 8. LAI treatment continuation: a TEAE with onset at or after
week 8 and prior to the completion visit (week 28). TEAEs that in-
creased in severity across periods were counted in both periods.
3. Results
3.1. Patient disposition and exposure
The study randomized 295 patients of whom 67.6% (100/148) in the
AOM 400 and 56.5% (83/147) in the PP group completed 28 weeks of
treatment (Fig. 2). At baseline, the treated patients (n=281) were sta-
ble and showed similar characteristics as well as similar levels of func-
tional impairment and psychopathology between treatment groups
(Table 1). The mean dose of AOM 400 at week 24 was 387 ± 3.4 mg
(±SE). The mean PP dose at week 24 of the study was 110 ± 3.6 mg
(±SE, EU dosing) equivalent to 172 mg (US dosing).
3.2. Effectiveness outcomes
Analysis of the pre-deﬁned primary endpoint showed a least squares
mean (LSM) change from baseline to week 28 on QLS total score of
7.47 ± 1.53 for AOM 400 (n=136) and 2.80 ± 1.62 for PP (n=132).
The LSM difference between treatments was 4.67 (95%CI: [0.32;9.02],
p=0.036) conﬁrming non-inferiority of AOM 400 compared to PP as
the lower bound of the 95%CI was N−5. Sensitivity analyses of the pri-
mary endpoint all demonstrated non-inferiority of AOM400 vs PP using
MMRMwith the PPS, LOCF ANCOVAwith the FAS and OC ANCOVAwith
the FAS. Superiority was then tested as pre-speciﬁed with the FAS and
demonstrated for AOM 400 over PP, since the lower bound of the
95%CI was N0. Improvements on QLS total scores for AOM 400 vs PP
were signiﬁcant at 8 weeks of treatment and at all subsequent visits
(Fig. 3A).
AOM 400 treatment also resulted in signiﬁcant improvements rela-
tive to PP in CGI-S (Fig. 3B) and IAQ scores (Table 2). The LSMdifference
between treatments in change from baseline to week 28 on CGI-S score
was−0.28 (95%CI: [−0.48;−0.09], p=0.004).
Pre-deﬁned secondary analyses of change from baseline to week 28
in QLS domain scores showed that the intrapsychic foundations domain
of the QLS signiﬁcantly improved after AOM400 treatment as compared
to PP treatment, whereas the treatment differences, although in favor of
AOM 400, did not reach signiﬁcance in the other QLS domains (Table 3).
Additional pre-deﬁned analyses of secondary outcomes found sig-
niﬁcant LSM treatment differences at week 28 favoring AOM 400 vs
PP in patients ≤35 years on QLS (10.7, 95%CI: [0.70;20.7], p=0.037),
CGI-S (−0.44, 95%CI: [−0.83; −0.06], p=0.026), and IAQ (−2.65,
95%CI: [−5.28;−0.02], p=0.048) (Fig. 4, Table 2). Similar analyses in
patients N35 years showed no signiﬁcant LSM treatment differences
on QLS (2.81, 95%CI: [−2.02;7.63], p=0.25), CGI-S (−0.22, 95%CI:
[−0.44;0.01], p=0.061), or IAQ (−1.02, 95%CI: [−2.77;0.73],
p=0.25).atiﬁed subgroups.
LSM difference, AOM 400 vs PP (95% CI)a p-Value
1)
−1.49 (−2.94,−0.05) 0.043
)
−2.65 (−5.28,−0.02) 0.048
)
−1.02 (−2.77, 0.73) 0.250
t week 28. IAQmeasures treatment effectiveness relative to previousmedication. Patients
Table 3
Effects of AOM 400 and PP treatment on QLS domain scores from baseline to week 28.
LSM change from baseline to week 28 (SE) LSM difference, AOM 400 vs PP (95% CI)a p-Value
AOM 400 (n=136) PP (n=132)
Common objects and activities 0.52 (0.16) 0.18 (0.17) 0.33 (−0.12, 0.78) 0.149
Intrapsychic foundations 2.25 (0.59) 0.50 (0.63) 1.75 (0.09, 3.41) 0.039
Interpersonal relations 3.24 (0.68) 1.47 (0.72) 1.76 (−0.14, 3.67) 0.070
Instrumental role 1.76 (0.42) 0.83 (0.45) 0.92 (−0.28, 2.12) 0.130
LSM: least squares mean, SE: standard error.
a Pre-deﬁned secondary analysis used similarMMRManalyses as for the primary endpoint to assess changes from baseline on individual QLS domains toweek 28 in the full analysis set.
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AEs were the most frequent reason for discontinuation; AOM 400:
11.1% (16/144), PP: 19.7% (27/137). All-cause discontinuations, discon-
tinuations due to AEs and withdrawal of consent were numerically
lower for AOM 400 as compared to PP (Fig. 2).
TEAEs occurring in ≥5% of patients in either treatment group are
shown in Table 4. The most frequent TEAEs in the treatment continua-
tion phase (themain period of interest with respect to safety evaluation
of AOM 400 vs PP) were increased weight, psychotic disorder, and
insomnia, which were all more frequent in PP-treated patients. TEAEs
related to extrapyramidal symptoms, including akathisia, were low
and occurred at rates less than 5% in both groups. In treated patients,
the absolute mean change (±SD) in body weight from baseline to
week 28 was 0.2 ± 5.9 kg (n=100) for AOM 400 and 1.4 ± 6.6 kg for
PP (n=83). Furthermore, the incidences of potential clinically
signiﬁcant weight gain (≥7% change from baseline) at any time post-
baseline were 16/144 (11.1%) for AOM 400 and 20/137 (14.6%) for PP,
while corresponding incidences of weight loss were 14/144 (9.7%) for
AOM 400 and 8/137 (5.8%) for PP. No new safety signals were detected
in either treatment group, and the incidence of serious AEs was low
with both treatments. No deaths occurred during the study.Fig. 4. Effects of AOM 400 and PP treatment on QLS total score (A) and CGI-S score (B) in
patients ≤35 years and in those N35 years. This pre-deﬁned analysis assessed least squares
mean (LSM) changes from baseline in age-stratiﬁed subgroups using samemethod as for
the primary endpoint (MMRM, FAS). *p b 0.05, **p b 0.01 indicate signiﬁcant differences
between treatments (AOM400 vs PP) within each age-group. Error bars indicate the stan-
dard error of the LSM. In treated patients ≤35 years, baseline QLS scores were 67.5 ± 21.6
for AOM 400 and 64.1 ± 24.6 for PP, baseline CGI-S scores were 3.95± 0.62 for AOM 400
and 4.00±0.57 for PP; in treated patients N35 years, baselineQLS scoreswere 65.7±21.3
for AOM 400 and 61.9 ± 20.1 for PP, baseline CGI-S scores were 4.01± 0.67 for AOM 400
and 3.96 ± 0.68 for PP.4. Discussion
The pre-deﬁned primary endpoint showing superior improvements
with AOM 400 vs PP on health-related quality of lifemeasuredwith QLS
was supported by secondary outcomemeasures (CGI-S and IAQ) show-
ing greater improvements in clinical symptomsand treatment effective-
ness with AOM 400 vs PP.
Although this study was randomized, it was designed to be more
naturalistic than traditional pivotal studies with regards to inclusion
criteria. The low frequency of screening failures (22.6%) suggests that
the study did not recruit a highly selected patient group, which is con-
sistent with a naturalistic setting. A health-related quality-of-life mea-
sure was selected as the primary endpoint in order to capture beneﬁts
beyond traditional measures of symptomatic efﬁcacy. Therefore, these
study results may be expected to be relevant to patient populations in
a real-world setting.
This study is the ﬁrst to use a health-related quality-of-life scale as
primary endpoint to compare two LAIs in the treatment of schizophre-
nia and is also the ﬁrst to show superiority of one atypical LAI over an-
other. The numerical LSM changes from baseline to week 28 in the
AOM 400 group observed in the primary analysis of QLS total score
(7.47 points)may, in contrast to PP (2.80 points), be considered clinical-
ly relevant (Jones et al., 2006; Thwin et al., 2013). The difference in QLS
total scores between AOM 400 and PP in LSM change from baseline to
week 28 (4.67 points) is close to theminimal clinically important differ-
ence of 5.3 points previously deﬁned (Falissard et al., in press). The QLS
domain analysis suggests that improvements in the underlying intra-
psychic foundations, such as sense of purpose, curiosity, empathy, and
emotional interaction, contribute most to the greater improvement in
functioning observed onQLS total scoreswith AOM400 vs PP treatmentin patients with schizophrenia. Typical efﬁcacy assessments do not
focus on the more subtle aspects of social functioning that deﬁne the
richness of personal experience. We speculate that the improvements
on health-related quality of life and functioning with AOM 400 vs PP
may be attributed to the characteristics and proﬁle of the therapeutical-
ly active molecule. In contrast to paliperidone, which completely blocks
dopamine D2 receptors, aripiprazole is a partial agonist at dopamine D2
receptors, which are hypothesized tomodulate dopaminergic activity in
the brain, thereby reducing positive symptoms and potentially improv-
ing negative and cognitive symptoms (Lieberman, 2004).
AOM 400 showed greater effectiveness than PP on primary and sec-
ondary endpoints in the total study population. In pre-deﬁned analyses,
similar signiﬁcant effects with AOM 400 vs PP were consistently found
in patients ≤35 years. Numerically larger improvements from baseline
were also observed after AOM 400 treatment compared with PP in pa-
tients N35 years, but no signiﬁcant differences were shown. Based on
the positive effect of AOM 400 in younger patients, an early treatment
start may help to protect patients from subsequent deterioration in
Table 4
Treatment-emergent adverse events (TEAEs) by treatment group and phase.a
Treatment phase: Oral conversion LAI initiation LAI continuation
Treatment group: AOM 400 (n=144) PP (n=137) AOM 400 (n=132) PP (n=118) AOM 400 (n=119) PP (n=109)
n (%):
Any TEAE 50 (34.7) 53 (38.7) 55 (41.7) 51 (43.2) 62 (52.1) 72 (66.1)
Any SAE 2 (1.4) 1 (0.7) 2 (1.5) 1 (0.8) 6 (5.0) 8 (7.3)
TEAE leading to discontinuation 6 (4.2) 10 (7.3) 4 (3.0) 6 (5.1) 6 (5.0) 13 (11.9)
Speciﬁc TEAEs occurring in ≥5% of patients in any group, n (%):
Accidental overdoseb 11 (7.6) 11 (8.0) 19 (14.4) 2 (1.7) 2 (1.7) 1 (0.9)
Injection site pain N/A N/A 1 (0.8) 10 (8.5) 3 (2.5) 1 (0.9)
Insomnia 11 (7.6) 4 (2.9) 4 (3.0) 8 (6.8) 3 (2.5) 6 (5.5)
Nausea 2 (1.4) 8 (5.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9)
Psychotic disorder 2 (1.4) 0 (0.0) 2 (1.5) 0 (0.0) 3 (2.5) 6 (5.5)
Weight increased 0 (0.0) 2 (1.5) 1 (0.8) 1 (0.8) 12 (10.1) 17 (15.6)
TEAEs related to extrapyramidal symptoms, n (%):
Akathisia 4 (2.8) 2 (1.5) 3 (2.3) 3 (2.5) 2 (1.7) 2 (1.8)
Dystonia 1 (0.7) 0 (0.0) 2 (1.5) 1 (0.8) 1 (0.8) 0 (0.0)
Extrapyramidal disorder 0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Muscle rigidity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0)
Muscle spasms 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9)
Tremor 0 (0.0) 0 (0.0) 1 (0.8) 2 (1.7) 2 (1.7) 2 (1.8)
AOM 400: aripiprazole once-monthly 400 mg, LAI: long-acting injectable, PP: paliperidone palmitate once-monthly, SAE: serious adverse event.
a Results shown from the safety sample (all treated patients).
b Some patients tookmore tablets than prescribed, in particular during the switch from oral medication to LAI treatment. These occurrences (monitored by pill counts at all visits) were
reported as TEAEs ‘accidental overdose’ even though they were not SAEs and had no clinical relevance.
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These results speak in favor of initiating treatment with AOM 400 in
younger patients as the greater treatment effectiveness may be particu-
larly pronounced in this patient subgroup.
Both treatments were generally well tolerated, and the incidence of
speciﬁc TEAEs was in line with the tolerability proﬁle of AOM 400 and
PP described in previous studies (Fleischhacker et al., 2013; Nasrallah
et al., 2010). Due to the differences in the LAI initiation phase between
AOM 400 and PP, the most valid comparison of tolerability between
AOM 400 and PP is in the LAI continuation phase, where rates of com-
mon TEAEs were generally higher with PP as compared to AOM 400
treatment. Higher rates of TEAEs are consistent with the higher discon-
tinuation rate due to AEs and numerically higher all-cause discontinua-
tions with PP vs AOM 400. Overall, 44/148 (29.7%) receiving AOM 400
discontinued treatment compared to 54/147 (36.7%) receiving PP; dis-
continuations from the study for lack of efﬁcacy were low in both treat-
ment groups, and differences were neither statistically nor clinically
signiﬁcant.
As a randomized open-label study, certain limitations of the study
are present. The patients' willingness to take LAImedication and knowl-
edge of treatment assignment may have biased reporting. The treat-
ment differences rated by the blinded clinician (QLS and IAQ) were
similar to those rated by the non-blinded clinician (CGI-S). Although
superior effectiveness of AOM 400 vs PP was found in the current
study cohort, all patients should be evaluated on an individual basis
for appropriate treatment choices.
5. Conclusions
In a head-to-head comparison, treatment with AOM 400 showed
superior improvements to PP on health-related quality of life as mea-
sured with the clinician-rated QLS in schizophrenia. The observed
changes in the QLS total score represent a clinically relevant improve-
ment in functioning, including sense of purpose, motivation, empathy,
and emotional interaction. The primary results were supported by sig-
niﬁcant treatment differences in CGI-S and IAQ scores, indicating an im-
provement in clinical symptoms and better effectiveness with AOM 400
compared to PP. In addition to improvements in symptoms and func-
tioning, a favorable tolerability proﬁle including lower incidences of
relevant AEs and a numerically lower all-cause discontinuation rate
suggest greater overall effectiveness for AOM 400 vs PP. In pre-deﬁned analyses, signiﬁcantly greater improvements with AOM 400
vs PP were consistently demonstrated in patients ≤35 years, indicating
that younger patients may beneﬁt in particular from AOM 400 com-
pared to PP treatment.
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